These novel therapies , Tirzepatide , represent a remarkable advancement in managing obesity and conceivably other disorders. They all are classified as GLP-1 pathway stimulators, signifying they to replicate the body's GLP-1 substance , stimulating insulin release and suppressing appetite . Desp